<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0120-2448</journal-id>
<journal-title><![CDATA[Acta Medica Colombiana]]></journal-title>
<abbrev-journal-title><![CDATA[Acta Med Colomb]]></abbrev-journal-title>
<issn>0120-2448</issn>
<publisher>
<publisher-name><![CDATA[Asociacion Colombiana de Medicina Interna]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0120-24482021000400008</article-id>
<article-id pub-id-type="doi">10.36104/amc.2021.2091</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[The efficacy of dual therapy for eradicating H. pylori in a Colombian population]]></article-title>
<article-title xml:lang="es"><![CDATA[Eficacia de la terapia dual para la erradicación de H. pylori en una población colombiana]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[BUITRAGO-LAGUADO]]></surname>
<given-names><![CDATA[JOHANNA]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[RUIZ-LINARES]]></surname>
<given-names><![CDATA[CARLOS]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[OTERO-REGINO]]></surname>
<given-names><![CDATA[WILLIAM ALBERTO]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad Nacional de Colombia Hospital Universitario Nacional de Colombia ]]></institution>
<addr-line><![CDATA[Bogotá D.C.]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad Nacional de Colombia Hospital Universitario Nacional de Colombia ]]></institution>
<addr-line><![CDATA[Bogotá D.C.]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Universidad Nacional de Colombia Hospital Universitario Nacional de Colombia ]]></institution>
<addr-line><![CDATA[Bogotá D.C.]]></addr-line>
<country>Colombia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2021</year>
</pub-date>
<volume>46</volume>
<numero>4</numero>
<fpage>8</fpage>
<lpage>13</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S0120-24482021000400008&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S0120-24482021000400008&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S0120-24482021000400008&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Background: Helicobacter pylori (H. pylori) affects 50% of the human population. The efficacy of the usual treatments has decreased due to increased antibiotic resistance, except for that of amoxicillin, tetracycline, furazolidone and bismuth. Recently, there has been a new interest in dual therapy with high-dose proton pump inhibitors (PPI) and amoxicillin as initial and rescue treatment. There are no studies on this topic in our setting.  Objective: to determine the efficacy of dual therapy with high-dose IPP and amoxicillin for eradicating H. pylori.  Materials and methods: this was a quasi-experimental study carried out from December 2019 to July 2020 in people over the age of 18 with histologically confirmed H. pylori. All received 40 mg of esomeprazole half an hour before breakfast, lunch and dinner, plus 1 gram of oral amoxicillin every eight hours for 14 days. Eradication was determined by fecal antigens (OnSiteTM H. pylori Biotech Inc.) after four weeks of treatment.  Results: 108 patients with an average age of 67 years were included, 70% of whom were women. Eradication per protocol (PP) and intention to treat (ITT) was 86% (95%CI 79.4-92.5%) for both. In previously treated patients (26%) the efficacy was 85.7% (95%CI 71.8-99.5%). Adverse events were mild in 31%, especially nausea (16%) and abdominal distension (14%). Treatment was not suspended in any patient.  Conclusion: Dual therapy is effective, easy to administer, and has few adverse effects. It would be a good option in our setting as initial or rescue therapy. Larger studies are needed to confirm our results. (Acta Med Colomb 2021; 46. DOI:https://doi.org/10.36104/amc.2021.2091).]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Antecedentes: Helicobacter pylori (H. pylori) afecta a 50% de la humanidad. Los tratamientos usuales han disminuido su eficacia por aumento de la resistencia a los antibióticos, excepto: amoxicilina, tetraciclina, furazolidona y bismuto. Recientemente hay un nuevo interés en la terapia dual con altas dosis de inhibidores de bomba de protones (IBP) y amoxicilina como terapia inicial y como rescate. En nuestro medio no hay estudios al respecto.  Objetivo: determinar la eficacia de la terapia dual con altas dosis de IBP y amoxicilina para erradicar H. pylori.  Material y métodos: estudio cuasiexperimental realizado entre diciembre de 2019 y julio de 2020 en mayores de 18 años, con H.pylori identificado histológicamente. Todos recibieron esomeprazol 40 mg media hora antes de desayuno, almuerzo y cena mas amoxicilina 1 gramo oral cada 8 horas por 14 días. La erradicación se determinó con antígenos fecales (OnSiteTM H. pylori Biotech Inc) después de cuatro semanas del tratamiento.  Resultados: se incluyeron 108 pacientes, con edad promedio de 67 años, 70% mujeres. La erradicación por protocolo (PP) e intención de tratar (ITT) fue de 86% (IC95% 79.4-92.5%) para ambos. En los pacientes con tratamiento previo (26%) la eficacia fue de 85.7% (IC95% 71.8-99.5%). Los eventos adversos fueron leves en 31%, especialmente náuseas (16%) y distensión abdominal (14%). En ninguno se suspendió el tratamiento.  Conclusión: la terapia dual es eficaz, fácil de administrar y con pocos efectos adversos. Sería una buena opción en nuestro medio como terapia inicial y como rescate. Se requieren estudios más grandes para verificar nuestros resultados. (Acta Med Colomb 2021; 46. DOI:https://doi.org/10.36104/amc.2021.2091).]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Helicobacter pylori]]></kwd>
<kwd lng="en"><![CDATA[dual therapy]]></kwd>
<kwd lng="en"><![CDATA[proton pump inhibitor]]></kwd>
<kwd lng="en"><![CDATA[amoxicillin]]></kwd>
<kwd lng="es"><![CDATA[Helicobacter pylori]]></kwd>
<kwd lng="es"><![CDATA[terapia dual]]></kwd>
<kwd lng="es"><![CDATA[inhibidor de bomba de protones]]></kwd>
<kwd lng="es"><![CDATA[amoxicilina]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hooi]]></surname>
<given-names><![CDATA[JKY]]></given-names>
</name>
<name>
<surname><![CDATA[Lai]]></surname>
<given-names><![CDATA[WY]]></given-names>
</name>
<name>
<surname><![CDATA[Ng]]></surname>
<given-names><![CDATA[WK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis]]></article-title>
<source><![CDATA[Gastroenterology]]></source>
<year>2017</year>
<volume>153</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>420-9</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kalali]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Formichella]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Gerhard]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diagnosis of Helicobacter pylori: Changes towards the Future]]></article-title>
<source><![CDATA[Diseases]]></source>
<year>2015</year>
<volume>3</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>122-35</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Malfertheiner]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Megraud]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[O'Morain]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Management of helicobacter pylori infection-the Maastricht V/Florence consensus report]]></article-title>
<source><![CDATA[Gut]]></source>
<year>2017</year>
<volume>66</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>6-30</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hu]]></surname>
<given-names><![CDATA[Q]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Fu]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Gastric mucosa-associated lymphoid tissue lymphoma and Helicobacter pylori infection: A review of current diagnosis and management]]></article-title>
<source><![CDATA[Biomark Res]]></source>
<year>2016</year>
<volume>4</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-9</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sugano]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Tack]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Kuipers]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Kyoto global consensus report on Helicobacter pylori gastritis]]></article-title>
<source><![CDATA[Gut]]></source>
<year>2015</year>
<volume>64</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1353-67</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gisbert]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Molina-Infante]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Amador]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[IV Conferencia Española de Consenso sobre el tratamiento de la infección por Helicobacter pylori]]></article-title>
<source><![CDATA[Gastroenterol Hepatol]]></source>
<year>2016</year>
<volume>39</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>697-721</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Otero]]></surname>
<given-names><![CDATA[RW]]></given-names>
</name>
<name>
<surname><![CDATA[Gómez]]></surname>
<given-names><![CDATA[ZM]]></given-names>
</name>
<name>
<surname><![CDATA[Otero]]></surname>
<given-names><![CDATA[PL]]></given-names>
</name>
<name>
<surname><![CDATA[Trespalacios]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Helicobacter pylori: ¿cómo se trata en el 2018?]]></article-title>
<source><![CDATA[Rev Gastroenterol Peru]]></source>
<year>2018</year>
<volume>38</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>54-63</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Molina-Infante]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Shiotani]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Practical Aspects in Choosing a Helicobacter pylori Therapy]]></article-title>
<source><![CDATA[Gastroenterol Clin North Am]]></source>
<year>2015</year>
<volume>44</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>519-35</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Camargo]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[García]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Riquelme]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Systematic Review in Latin America]]></article-title>
<source><![CDATA[Am J Gastroenterol]]></source>
<year>2014</year>
<volume>109</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>485-95</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Liao]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Zheng]]></surname>
<given-names><![CDATA[Q]]></given-names>
</name>
<name>
<surname><![CDATA[Liang]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of fluoroquinolone resistance on 14-day levofloxacin triple and triple plus bismuth quadruple therapy]]></article-title>
<source><![CDATA[Helicobacter]]></source>
<year>2013</year>
<volume>18</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>373-7</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Liang]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Xu]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Zheng]]></surname>
<given-names><![CDATA[Q]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy of bismuth-containing quadruple therapies for clarithromycin-, metronidazole-, and fluoroquinolone-resistant helicobacter pylori infections in a prospective study]]></article-title>
<source><![CDATA[Clin Gastroenterol Hepatol]]></source>
<year>2013</year>
<volume>11</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>802-807.e1</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Henao Riveros]]></surname>
<given-names><![CDATA[SC]]></given-names>
</name>
<name>
<surname><![CDATA[Quiroga]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez Marín]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
<name>
<surname><![CDATA[Otero Regino]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Resistencia primaria a la claritromicina en aislamientos de Helicobacter pylori]]></article-title>
<source><![CDATA[Rev colomb gastroenterol]]></source>
<year>2009</year>
<volume>24</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>110-4</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Arévalo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Otero]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Trespalacios]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Helicobacter pylori: resistencia múltiple en pacientes de Bogotá, Colombia]]></article-title>
<source><![CDATA[Biomédica]]></source>
<year>2019</year>
<volume>39</volume>
<page-range>125-34</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Trespalacios-Rangél]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Otero]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Arévalo-Galvis]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Poutou-Piñales]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Rimbara]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Graham]]></surname>
<given-names><![CDATA[DY]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Surveillance of levofloxacin resistance in helicobacter pylori isolates in Bogotá-Colombia (2009-2014)]]></article-title>
<source><![CDATA[PLoS One]]></source>
<year>2016</year>
<volume>11</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1-10</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Graham]]></surname>
<given-names><![CDATA[DY]]></given-names>
</name>
<name>
<surname><![CDATA[Shiotani]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Newer concepts regarding resistance in the treatment Helicobacter pylori infections]]></article-title>
<source><![CDATA[Nat Clin Pr Gastroenterol Hepatol]]></source>
<year>2008</year>
<volume>5</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>321-31</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gisbert]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[McNicholl]]></surname>
<given-names><![CDATA[AG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Optimization strategies aimed to increase the efficacy of H. pylori eradication therapies]]></article-title>
<source><![CDATA[Helicobacter]]></source>
<year>2017</year>
<volume>22</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>1-13</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Villoria]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Garcia]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Calvet]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Gisbert]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Vergara]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Meta-analysis: High-dose proton pump inhibitors vs. standard dose in triple therapy for Helicobacter pylori eradication]]></article-title>
<source><![CDATA[Aliment Pharmacol Ther]]></source>
<year>2008</year>
<volume>28</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>868-77</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yu]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Luo]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Long]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[High-dose PPI-amoxicillin dual therapy with or without bismuth for first-line Helicobacter pylori therapy: A randomized trial]]></article-title>
<source><![CDATA[Helicobacter]]></source>
<year>2019</year>
<volume>24</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>1-7</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hu]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Optimized high-dose amoxicillin dual therapies fail to achieve high cure rates in China]]></article-title>
<source><![CDATA[Saudi J Gastroenterol]]></source>
<year>2017</year>
<volume>23</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>275-80</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bayerdorffer]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Miehlke]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Mannes]]></surname>
<given-names><![CDATA[GA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Double-blind trial of omeprazole and amoxicillin to cure Helicobacter pylori infection in patients with duodenal ulcers]]></article-title>
<source><![CDATA[Gastroenterology]]></source>
<year>1995</year>
<volume>108</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>1412-7</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bayerdorffer]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Rudolph]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Neubauer]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori infection]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>1995</year>
<volume>345</volume>
<numero>8965</numero>
<issue>8965</issue>
<page-range>1591-4</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Malfertheiner]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Current European concepts in the management of Helicobacter pylori infection. The Maastricht consensus report]]></article-title>
<source><![CDATA[Gut]]></source>
<year>1997</year>
<volume>41</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>8-13</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Graham]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Lu]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Shiotani]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Failure of optimized dual proton pump inhibitor amoxicillin therapy: What now?]]></article-title>
<source><![CDATA[Saudi J Gastroenterol]]></source>
<year>2017</year>
<volume>23</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>265-7</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Fan]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Eradication Efficacy of Modified Dual Therapy Compared with Bismuth-Containing Quadruple Therapy as a First-Line Treatment of Helicobacter pylori]]></article-title>
<source><![CDATA[Am J Gastroenterol]]></source>
<year>2019</year>
<volume>114</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>437-45</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Lin]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[HL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[High-dose dual therapy is superior to standard first-line or rescue therapy for helicobacter pylori infection]]></article-title>
<source><![CDATA[Clin Gastroenterol Hepatol]]></source>
<year>2015</year>
<volume>13</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>895-905.e5</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Scott]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Weeks]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Melchers]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Sachs]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The life and death of Helicobacter pylori]]></article-title>
<source><![CDATA[Gut]]></source>
<year>1998</year>
<volume>43</volume>
<numero>^s1</numero>
<issue>^s1</issue>
<supplement>1</supplement>
<page-range>56-60</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[El Rouby]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Lima]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Johnson]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine]]></article-title>
<source><![CDATA[Expert Opin Drug Metab Toxicol]]></source>
<year>2018</year>
<volume>14</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>447-60</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sim]]></surname>
<given-names><![CDATA[SC]]></given-names>
</name>
<name>
<surname><![CDATA[Risinger]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Dahl]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants]]></article-title>
<source><![CDATA[Clin Pharmacol Ther]]></source>
<year>2006</year>
<volume>79</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>103-13</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Deshpande N]]></surname>
<given-names><![CDATA[V. S]]></given-names>
</name>
<name>
<surname><![CDATA[Ravi]]></surname>
<given-names><![CDATA[RK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Rapid and ultra-rapid metabolizers with CYP2C19*17 polymorphism do not respond to standard therapy with proton pump inhibitors]]></article-title>
<source><![CDATA[Meta Gene]]></source>
<year>2016</year>
<volume>9</volume>
<page-range>159-64</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Arévalo Galvis]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Trespalacios Rangel]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Otero Regino]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Personalized therapy for Helicobacter pylori: CYP2C19 genotype effect on first-line triple therapy]]></article-title>
<source><![CDATA[Helicobacter]]></source>
<year>2019</year>
<volume>24</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>1-11</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Suzuki]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Gotoda]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Kusano]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<source><![CDATA[day vonoprazan and low- dose amoxicillin dual therapy as first- line Helicobacter pylori treatment: a multicentre randomised trial in Japan]]></source>
<year>2020</year>
<page-range>1-8</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dixon]]></surname>
<given-names><![CDATA[MF]]></given-names>
</name>
<name>
<surname><![CDATA[Genta]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
<name>
<surname><![CDATA[Yardley]]></surname>
<given-names><![CDATA[HJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Classification and grading of gastritis. The updated Sydney System]]></article-title>
<source><![CDATA[Am J Surg Pathol]]></source>
<year>1996</year>
<volume>20</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1161-81</page-range></nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rugge]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Correa]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Di Mario]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[OLGA staging for gastritis: A tutorial]]></article-title>
<source><![CDATA[Dig Liver Dis]]></source>
<year>2008</year>
<volume>40</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>650-8</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Otero]]></surname>
<given-names><![CDATA[R. W]]></given-names>
</name>
<name>
<surname><![CDATA[Trespalacios]]></surname>
<given-names><![CDATA[R. AA]]></given-names>
</name>
<name>
<surname><![CDATA[Otero]]></surname>
<given-names><![CDATA[P. L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Guía de práctica clínica para el diagnóstico y tratamiento de la infección por Helicobacter pylori en adultos]]></article-title>
<source><![CDATA[Rev Colomb Gastroenterol]]></source>
<year>2015</year>
<volume>30</volume>
<page-range>17-33</page-range></nlm-citation>
</ref>
<ref id="B35">
<label>35</label><nlm-citation citation-type="">
<collab>Farmalatina</collab>
<source><![CDATA[Prueba Rápida OnSite H. pylori Ag -Casete (Muestra Fecal)]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B36">
<label>36</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tang]]></surname>
<given-names><![CDATA[HL]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Hu]]></surname>
<given-names><![CDATA[YF]]></given-names>
</name>
<name>
<surname><![CDATA[Xie]]></surname>
<given-names><![CDATA[HG]]></given-names>
</name>
<name>
<surname><![CDATA[Di]]></surname>
<given-names><![CDATA[Zhai S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effects of CYP2C19 Loss-of-Function Variants on the Eradication of H. pylori Infection in Patients Treated with Proton Pump Inhibitor-Based Triple Therapy Regimens: A Meta-Analysis of Randomized Clinical Trials]]></article-title>
<source><![CDATA[PLoS One]]></source>
<year>2013</year>
<volume>8</volume>
<numero>4</numero>
<issue>4</issue>
</nlm-citation>
</ref>
<ref id="B37">
<label>37</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gao]]></surname>
<given-names><![CDATA[CP]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[PPI-amoxicillin dual therapy for Helicobacter pylori infection: An update based on a systematic review and meta-analysis]]></article-title>
<source><![CDATA[Helicobacter]]></source>
<year>2020</year>
<volume>25</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>1-8</page-range></nlm-citation>
</ref>
<ref id="B38">
<label>38</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tai]]></surname>
<given-names><![CDATA[WC]]></given-names>
</name>
<name>
<surname><![CDATA[Liang]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Kuo]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A 14 day esomeprazole- And amoxicillin-containing high-dose dual therapy regimen achieves a high eradication rate as first-line anti-Helicobacter pylori treatment in Taiwan: a prospective randomized trial]]></article-title>
<source><![CDATA[J Antimicrob Chemother]]></source>
<year>2019</year>
<volume>74</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1718-24</page-range></nlm-citation>
</ref>
<ref id="B39">
<label>39</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhu]]></surname>
<given-names><![CDATA[YJ]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[TY]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[High dose PPI-amoxicillin dual therapy for the treatment of Helicobacter pylori infection: a systematic review with meta-analysis]]></article-title>
<source><![CDATA[Therap Adv Gastroenterol]]></source>
<year>2020</year>
<volume>13</volume>
<page-range>1-12</page-range></nlm-citation>
</ref>
<ref id="B40">
<label>40</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pan]]></surname>
<given-names><![CDATA[KF]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Gerhard]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A large randomised controlled intervention trial to prevent gastric cancer by eradication of Helicobacter pylori in Linqu County, China: Baseline results and factors affecting the eradication]]></article-title>
<source><![CDATA[Gut]]></source>
<year>2016</year>
<volume>65</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>9-18</page-range></nlm-citation>
</ref>
<ref id="B41">
<label>41</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Itskoviz]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Boltin]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Leibovitzh]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Smoking increases the likelihood of Helicobacter pylori treatment failure]]></article-title>
<source><![CDATA[Dig Liver Dis]]></source>
<year>2017</year>
<volume>49</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>764-8</page-range></nlm-citation>
</ref>
<ref id="B42">
<label>42</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Suzuki]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Matsuo]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Ito]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Smoking increases the treatment failure for Helicobacter pylori eradication]]></article-title>
<source><![CDATA[Am J Med]]></source>
<year>2006</year>
<volume>119</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>217-24</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
